Novo Nordisk A/S（NVO）のニュースとイベント

$39.130

+0.078 (+0.20%)終値時点

NVO のニュース

7.010-27CNBC

US Employers Cut GLP-1 Drug Coverage Amid Rising Costs

6.510-27Fool

Competitive Analysis of Pharmaceutical Giants

8.510-26Newsfilter

Biopharma Giants Invest Billions in Obesity Drug Manufacturing

9.510-25CNBC

Critical Earnings Week Ahead Amid Fed Meeting and Inflation Data

9.510-24CNBC

Biotech Sector Recovery: Moderna Leads the Charge

9.510-22Fool

Bristol-Myers Squibb Maintains Stable Revenue Growth

7.010-21Fool

Novo Nordisk's Outlook for the Next Decade

9.010-21Fool

Novo Nordisk Reports Promising Phase 3 Results for CagriSema

5.010-20Newsfilter

Novo's CagriSema Injection Shows Significant Weight Loss Potential

8.510-20CNBC

Novo Nordisk's CagriSema Shows Significant Weight Loss in Women

ニュースをもっと見る

NVO のイベント

10/26 17:00

Novo Nordisk Shares Rise to $39.15

Moderately bullish activity in Novo Nordisk (NVO), with shares up 10c, or 0.24%, near $39.15. Options volume relatively light with 26k contracts traded and calls leading puts for a put/call ratio of 0.83, compared to a typical level near 0.85. Implied volatility (IV30) is higher by 0.2 points near 39.54,and below the 52wk median, suggesting an expected daily move of $0.97. Put-call skew steepened, indicating increased demand for downside protection.Looking ahead: Novo Nordisk (NVO) will report earnings before the open on 2026-11-04.Option markets are pricing in a 50% probability of a move greater than 7.03% or $2.75.

10/23 14:30

FDA Approves Awiqli Injection for Pediatric Type 2 Diabetes

The U.S. Food and Drug Administration has approved Awiqli injection, a long-acting insulin analog, as an adjunct to diet and exercise to improve glycemic control in pediatric patients aged 10 years and older with type 2 diabetes mellitus. Awiqli is administered by subcutaneous injection once weekly. "Awiqli, which was approved for the same condition in adults earlier this year, is the first once-weekly insulin to be approved for children with type 2 diabetes mellitus," the FDA stated.

10/16 12:30

Mixed Options Sentiment in Novo Nordisk as Shares Drop to $39.16

Cboe data shows mixed options sentiment in Novo Nordisk (NVO), with shares down 6c near $39.16. Options volume relatively light with 18k contracts traded and calls leading puts for a put/call ratio of 0.44, compared to a typical level near 0.82. Implied volatility (IV30) dropped 0.26 near 40.3,and below the 52wk median, suggesting an expected daily move of $0.99. Put-call skew steepened, indicating increased demand for downside protection.Looking ahead: Novo Nordisk (NVO) will report earnings after the close on None.Option markets are pricing in a 50% probability of a move greater than 0.0% or $0.00.

10/16 06:30

U.S. Finds Poor Conditions at Two Chinese GLP-1 Drug Factories

Two Chinese factories making components for GLP-1 drugs in America were found to be in poor conditions, with U.S. inspectors noting black mold on equipment and "gross contamination" on the floors of one, Anna Edney of Bloomberg reports. Additionally, the inspectors caught employees trying to hide paperwork and evidence of bogus documentation. The two factories manufactured semaglutide and tirzepatide, the active ingredients in Novo Nordisk (NVO) and Eli Lilly's (LLY) GLP-1 drugs.

10/15 11:00

Novo Nordisk Shares Rise 2.9% to $39.23

Moderately bullish activity in Novo Nordisk (NVO), with shares up $1.10, or 2.9%, near $39.23. Options volume running well above average with 22k contracts traded and calls leading puts for a put/call ratio of 0.44, compared to a typical level near 0.85. Implied volatility (IV30) is higher by 0.7 points near 41.61,and below the 52wk median, suggesting an expected daily move of $1.03. Put-call skew steepened, indicating increased demand for downside protection.Looking ahead: Novo Nordisk (NVO) will report earnings after the close on None.Option markets are pricing in a 50% probability of a move greater than 0.0% or $0.00.

イベントをもっと見る

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。